By Elise Reuter | Published May 20, 2026
Medtronic, the global leader in medical technology, has announced a definitive agreement to acquire SPR Therapeutics, a move that signals a significant shift in the company’s pain management strategy. This acquisition—Medtronic’s third major deal in the 2026 calendar year—is set to bolster the company’s neuromodulation division by integrating SPR’s proprietary peripheral nerve stimulation (PNS) technology.
The deal, which is expected to close within the first half of Medtronic’s 2027 fiscal year, underscores a broader industry pivot toward non-opioid, minimally invasive alternatives for the management of chronic and acute pain.
Main Facts: A Strategic Addition to the Pain Management Arsenal
The core of this acquisition centers on the SPRINT Peripheral Nerve Stimulation (PNS) System. Unlike traditional spinal cord stimulators that require permanent surgical implantation and often carry the risks associated with long-term hardware, the SPRINT system offers a temporary, non-opioid solution.
The SPRINT device functions by placing a microscopic lead near a target nerve, which then provides electrical stimulation to alleviate pain. The system is designed to be worn for up to 60 days, acting as a bridge for patients who may not yet be candidates for permanent implants or who are looking for a drug-free alternative to manage their symptoms.
For Medtronic, this acquisition serves two strategic purposes:
- Diversification of Modalities: By adding a temporary PNS solution, Medtronic fills a critical gap in its "pain care continuum," moving from early-stage intervention to long-term neuromodulation.
- Market Penetration: The acquisition provides Medtronic with a mature, FDA-cleared technology that has already established a footprint in the clinical pain management space, allowing the company to leverage its massive sales and distribution network to scale the technology globally.
Chronology: The Evolution of SPRINT and Medtronic’s Growth Trajectory
The journey of the SPRINT technology and Medtronic’s aggressive acquisition strategy can be traced through several key milestones:
- August 2018: SPR Therapeutics secures FDA clearance for its SPRINT endura and extensa Peripheral Nerve Stimulation Systems. This clearance marked a turning point for the company, validating the clinical efficacy of short-term nerve stimulation for both acute and chronic pain.
- 2019–2024: During this period, SPR Therapeutics focused on clinical data collection and market adoption, gradually proving that their temporary system could effectively reduce pain scores and decrease the reliance on pharmacological interventions.
- December 2025: SPR Therapeutics reaches a major commercial milestone, announcing that its SPRINT device has been successfully utilized in over 50,000 implants. This volume provided the necessary real-world evidence to attract major players like Medtronic.
- Early 2026: Medtronic launches an aggressive acquisition campaign as part of its fiscal growth strategy, aiming to solidify its dominance in the neuromodulation sector.
- May 2026: Medtronic officially announces the acquisition of SPR Therapeutics.
- Fiscal Year 2027 (Projected): The deal is slated to close within the first half of the fiscal year, pending customary regulatory approvals and closing conditions.
Supporting Data: The Growing Need for Non-Opioid Solutions
The impetus for this deal is driven by a massive, unmet clinical need. According to data from the American Chronic Pain Association, nearly 50 million Americans suffer from chronic pain. The societal and economic burden of this epidemic is staggering, characterized by lost productivity, long-term healthcare utilization, and the ongoing risks of the opioid crisis.
Clinical Efficacy and Adoption
The SPRINT system’s appeal lies in its "less-is-more" approach. By avoiding the permanent placement of batteries or complex hardware, the device reduces the risk of surgical complications. With 50,000 successful cases under its belt, the technology has passed the "early adopter" phase and has reached a level of clinical maturity that fits well within Medtronic’s existing portfolio of premium, evidence-based devices.
Market Trends in Neuromodulation
The neuromodulation market is currently experiencing a transition from "last-resort" therapy to "early-intervention" therapy. Physicians are increasingly looking for ways to intervene before a patient’s pain becomes refractory or before the patient becomes dependent on high-dose opioids. The SPRINT system’s 60-day treatment window fits perfectly into this clinical workflow, offering a low-risk trial of neuromodulation that can either resolve the patient’s pain or serve as a diagnostic indicator for whether a permanent implant would be effective in the future.
Official Responses and Executive Insight
The leadership at Medtronic views this acquisition as a fundamental expansion of their clinical reach. Domenico De Paolis, the interim president of neuromodulation at Medtronic, provided a statement emphasizing the shift toward early intervention.
"Adding a temporary peripheral nerve stimulation option to our existing portfolio allows us to broaden access to treatment," De Paolis noted. "It enables physicians to intervene earlier in the patient’s journey, providing relief before chronic pain becomes a debilitating cycle."
The acquisition is not merely a product purchase; it is an integration of a philosophy. Medtronic’s leadership has been vocal about the need to provide "precision medicine" in the neuromodulation space, where one size does not fit all. By controlling both the short-term (SPRINT) and long-term (Implantable Spinal Cord Stimulation) solutions, Medtronic can now offer a comprehensive suite of products that guide a patient’s journey through the pain management system.
Implications: What This Means for the Future of Medtronic
The acquisition of SPR Therapeutics has several long-term implications for Medtronic, the competitive landscape, and the broader healthcare sector.
1. Competitive Positioning
Medtronic faces stiff competition in the neuromodulation space from companies like Boston Scientific and Abbott. By acquiring SPR Therapeutics, Medtronic effectively shuts off a potential acquisition target for its rivals and secures a unique technology that is currently difficult to replicate. This move forces competitors to re-evaluate their own portfolios, potentially sparking further consolidation in the nerve stimulation market.
2. Clinical Workflow Integration
One of the primary barriers to the adoption of neuromodulation has been the surgical complexity and the "barrier to entry" for primary care physicians and pain specialists. Because the SPRINT system is temporary and minimally invasive, it is easier to implement in outpatient surgery centers. Medtronic’s massive field sales force can now educate a broader base of physicians—beyond just neurosurgeons—on how to utilize this technology, potentially increasing the total addressable market for nerve stimulation devices.
3. Financial Impact
While specific financial terms of the deal were not disclosed, analysts suggest that the acquisition is a strategic "bolt-on" move designed to provide immediate revenue growth while enhancing the company’s long-term competitive moat. As the company moves into its 2027 fiscal year, the integration of SPR Therapeutics will be a key metric for investors to watch, particularly regarding how quickly Medtronic can scale SPRINT’s reach using its global distribution network.
4. Regulatory and Ethical Considerations
As with any acquisition of this size, regulatory scrutiny is expected. However, because SPR Therapeutics already has FDA clearance, the transition is expected to be relatively smooth compared to the acquisition of a pre-clinical startup. The focus will remain on ensuring that the integration does not disrupt the supply chain for current SPRINT users and that the clinical training programs for new physicians remain robust.
Conclusion
The acquisition of SPR Therapeutics is a clear signal that Medtronic is committed to capturing the full spectrum of the pain management market. By combining the agility of a temporary, non-opioid stimulation device with the massive clinical and commercial infrastructure of a global titan, Medtronic is positioning itself to address the chronic pain epidemic with a more nuanced, tiered approach to patient care. As the medical community continues to move away from systemic pharmacological treatments, the role of devices like SPRINT will likely grow, and Medtronic’s latest investment ensures they will be at the forefront of that transition.
